MiMedx Net Worth
MiMedx Net Worth Breakdown | MDXG |
MiMedx Net Worth Analysis
MiMedx's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including MiMedx's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of MiMedx's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform MiMedx's net worth analysis. One common approach is to calculate MiMedx's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares MiMedx's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing MiMedx's net worth. This approach calculates the present value of MiMedx's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of MiMedx's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate MiMedx's net worth. This involves comparing MiMedx's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into MiMedx's net worth relative to its peers.
Enterprise Value |
|
To determine if MiMedx is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding MiMedx's net worth research are outlined below:
| MiMedx Group had very high historical volatility over the last 90 days | |
| MiMedx Group is unlikely to experience financial distress in the next 2 years | |
| About 70.0% of the company shares are owned by institutional investors | |
| Latest headline from thefly.com: MiMedx price target raised by 1 at Cantor Fitzgerald, heres why MDXGORGO |
MiMedx Quarterly Good Will |
|
MiMedx uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in MiMedx Group. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to MiMedx's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
MiMedx Target Price Consensus
MiMedx target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. MiMedx's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 5 | Strong Buy |
Most MiMedx analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand MiMedx stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of MiMedx Group, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationMiMedx Target Price Projection
MiMedx's current and average target prices are 7.16 and 12.00, respectively. The current price of MiMedx is the price at which MiMedx Group is currently trading. On the other hand, MiMedx's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On MiMedx Target Price
Know MiMedx's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as MiMedx is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading MiMedx Group backward and forwards among themselves. MiMedx's institutional investor refers to the entity that pools money to purchase MiMedx's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Punch & Associates Inv Mgmt Inc | 2025-03-31 | 1.7 M | Millennium Management Llc | 2025-03-31 | 1.2 M | Charles Schwab Investment Management Inc | 2025-03-31 | 1.2 M | Northern Trust Corp | 2025-03-31 | 1.1 M | Goldman Sachs Group Inc | 2025-03-31 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 1.1 M | Harbor Capital Advisors Inc | 2025-03-31 | 1 M | Royal Bank Of Canada | 2025-03-31 | 982.5 K | Qube Research & Technologies | 2025-03-31 | 946.8 K | Essex Woodlands Health Ventures | 2025-03-31 | 28.2 M | Blackrock Inc | 2025-03-31 | 10.2 M |
Follow MiMedx's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.06 B.Market Cap |
|
Project MiMedx's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.18 | 0.19 | |
| Return On Capital Employed | 0.27 | 0.28 | |
| Return On Assets | 0.16 | 0.17 | |
| Return On Equity | 0.22 | 0.21 |
When accessing MiMedx's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures MiMedx's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of MiMedx's profitability and make more informed investment decisions.
Evaluate MiMedx's management efficiency
MiMedx Group has return on total asset (ROA) of 0.138 % which means that it generated a profit of $0.138 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2229 %, meaning that it created $0.2229 on every $100 dollars invested by stockholders. MiMedx's management efficiency ratios could be used to measure how well MiMedx manages its routine affairs as well as how well it operates its assets and liabilities. At this time, MiMedx's Return On Assets are most likely to increase slightly in the upcoming years. At this time, MiMedx's Return On Tangible Assets are most likely to increase slightly in the upcoming years. The MiMedx's current Return On Assets is estimated to increase to 0.17, while Non Currrent Assets Other are projected to decrease to roughly 652.5 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.31 | 1.38 | |
| Tangible Book Value Per Share | 1.10 | 1.16 | |
| Enterprise Value Over EBITDA | 20.74 | 21.78 | |
| Price Book Value Ratio | 7.32 | 6.96 | |
| Enterprise Value Multiple | 20.74 | 21.78 | |
| Price Fair Value | 7.32 | 6.96 | |
| Enterprise Value | 889 M | 447.8 M |
The management strategies employed by MiMedx's are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Enterprise Value Revenue 2.6484 | Revenue | Quarterly Revenue Growth 0.041 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MiMedx insiders, such as employees or executives, is commonly permitted as long as it does not rely on MiMedx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MiMedx insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
MiMedx Corporate Filings
10Q | 30th of July 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 28th of July 2025 Other Reports | ViewVerify | |
F4 | 7th of July 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 20th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
MiMedx Earnings Estimation Breakdown
The calculation of MiMedx's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of MiMedx is estimated to be 0.08 with the future projection ranging from a low of 0.08 to a high of 0.08. Please be aware that this consensus of annual earnings estimates for MiMedx Group is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.08 Lowest | Expected EPS | 0.08 Highest |
MiMedx Earnings Projection Consensus
Suppose the current estimates of MiMedx's value are higher than the current market price of the MiMedx stock. In this case, investors may conclude that MiMedx is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and MiMedx's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 5 | 73.05% | 0.0 | 0.08 | 0.21 |
MiMedx Earnings per Share Projection vs Actual
Actual Earning per Share of MiMedx refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering MiMedx Group predict the company's earnings will be in the future. The higher the earnings per share of MiMedx, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.MiMedx Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as MiMedx, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of MiMedx should always be considered in relation to other companies to make a more educated investment decision.MiMedx Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact MiMedx's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-07-29 | 2025-06-30 | 0.054 | 0.1 | 0.046 | 85 | ||
2025-04-28 | 2025-03-31 | 0.055 | 0.05 | -0.005 | 9 | ||
2025-02-26 | 2024-12-31 | 0.075 | 0.07 | -0.005 | 6 | ||
2024-10-30 | 2024-09-30 | 0.04 | 0.05 | 0.01 | 25 | ||
2024-07-31 | 2024-06-30 | 0.08 | 0.12 | 0.04 | 50 | ||
2024-04-30 | 2024-03-31 | 0.05 | 0.07 | 0.02 | 40 | ||
2024-02-28 | 2023-12-31 | 0.07 | 0.32 | 0.25 | 357 | ||
2023-10-30 | 2023-09-30 | 0.05 | 0.06 | 0.01 | 20 | ||
2023-08-01 | 2023-06-30 | -0.02 | -0.0046 | 0.0154 | 77 | ||
2023-05-02 | 2023-03-31 | -0.09 | -0.06 | 0.03 | 33 | ||
2023-02-28 | 2022-12-31 | -0.04 | -0.02 | 0.02 | 50 | ||
2022-11-02 | 2022-09-30 | -0.08 | -0.09 | -0.01 | 12 | ||
2022-08-02 | 2022-06-30 | -0.06 | -0.11 | -0.05 | 83 | ||
2022-05-03 | 2022-03-31 | -0.1 | -0.11 | -0.01 | 10 | ||
2022-02-28 | 2021-12-31 | -0.03 | 0.01 | 0.04 | 133 | ||
2021-11-02 | 2021-09-30 | -0.08 | -0.04 | 0.04 | 50 | ||
2021-08-03 | 2021-06-30 | -0.07 | -0.03 | 0.04 | 57 | ||
2021-04-28 | 2021-03-31 | -0.19 | -0.09 | 0.1 | 52 | ||
2021-03-08 | 2020-12-31 | -0.05 | -0.17 | -0.12 | 240 | ||
2020-08-04 | 2020-06-30 | 0.19 | -0.07 | -0.26 | 136 | ||
2020-06-30 | 2020-03-31 | 0 | -0.08 | -0.08 | 0 | ||
2020-03-17 | 2019-12-31 | 0.09 | 0.38 | 0.29 | 322 | ||
2019-10-31 | 2019-09-30 | 0.15 | 0.11 | -0.04 | 26 | ||
2019-07-31 | 2019-06-30 | 0.14 | -0.16 | -0.3 | 214 | ||
2019-04-26 | 2019-03-31 | 0.13 | -0.12 | -0.25 | 192 | ||
2019-02-21 | 2018-12-31 | 0.14 | -0.1247 | -0.2647 | 189 | ||
2018-10-25 | 2018-09-30 | 0.13 | -0.3318 | -0.4618 | 355 | ||
2018-07-26 | 2018-06-30 | 0.11 | 0.0162 | -0.0938 | 85 | ||
2018-04-26 | 2018-03-31 | 0.09 | 0.09 | 0.0 | 0 | ||
2018-02-28 | 2017-12-31 | 0.07 | 0.1 | 0.03 | 42 | ||
2017-10-26 | 2017-09-30 | 0.08 | 0.08 | 0.0 | 0 | ||
2017-07-26 | 2017-06-30 | 0.07 | 0.07 | 0.0 | 0 | ||
2017-04-28 | 2017-03-31 | 0.07 | 0.07 | 0.0 | 0 | ||
2017-02-23 | 2016-12-31 | 0.08 | 0.07 | -0.01 | 12 | ||
2016-10-27 | 2016-09-30 | 0.06 | 0.06 | 0.0 | 0 | ||
2016-07-26 | 2016-06-30 | 0.07 | 0.05 | -0.02 | 28 | ||
2016-04-25 | 2016-03-31 | 0.05 | 0.04 | -0.01 | 20 | ||
2016-02-23 | 2015-12-31 | 0.06 | 0.11 | 0.05 | 83 | ||
2015-10-29 | 2015-09-30 | 0.06 | 0.06 | 0.0 | 0 | ||
2015-07-30 | 2015-06-30 | 0.05 | 0.05 | 0.0 | 0 | ||
2015-04-27 | 2015-03-31 | 0.03 | 0.04 | 0.01 | 33 | ||
2015-02-26 | 2014-12-31 | 0.03 | 0.03 | 0.0 | 0 | ||
2014-10-30 | 2014-09-30 | 0.02 | 0.03 | 0.01 | 50 | ||
2014-04-25 | 2014-03-31 | -0.02 | -0.01 | 0.01 | 50 | ||
2014-02-26 | 2013-12-31 | -0.01 | -0.01 | 0.0 | 0 | ||
2013-07-31 | 2013-06-30 | -0.01 | -0.01 | 0.0 | 0 | ||
2013-05-01 | 2013-03-31 | -0.01 | -0.02 | -0.01 | 100 | ||
2013-03-07 | 2012-12-31 | -0.01 | -0.02 | -0.01 | 100 |
MiMedx Corporate Management
| Matthew Notarianni | Head Relations | Profile | |
| Todd Newton | Interim Director | Profile | |
| William Phelan | VP Officer | Profile | |
| Kimberly MaerskMoller | Chief Officer | Profile | |
| Kim Moller | Chief Officer | Profile | |
| Rebeccah Brown | Vice Affairs | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MiMedx Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MiMedx. If investors know MiMedx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MiMedx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.22) | Earnings Share 0.21 | Revenue Per Share | Quarterly Revenue Growth 0.041 | Return On Assets |
The market value of MiMedx Group is measured differently than its book value, which is the value of MiMedx that is recorded on the company's balance sheet. Investors also form their own opinion of MiMedx's value that differs from its market value or its book value, called intrinsic value, which is MiMedx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MiMedx's market value can be influenced by many factors that don't directly affect MiMedx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MiMedx's value and its price as these two are different measures arrived at by different means. Investors typically determine if MiMedx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MiMedx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.